Selvita expands its operations into the US
Posted: 21 September 2015 | Victoria White
Appreciating the importance of the US biotechnology and pharmaceutical market, Selvita decided to come closer to its partners and clients and open a fully-owned US subsidiary, Selvita Inc…
Selvita, the largest drug discovery company in Central and Eastern Europe, is establishing its first offices in the United States.
Appreciating the importance of the US biotechnology and pharmaceutical market, Selvita decided to come closer to its partners and clients and open a fully-owned US subsidiary, Selvita Inc. The new company will initially have two offices located in Greater Boston and in the San Francisco Bay areas.
“Massachusetts’ thriving life sciences community has become a magnet for investment by international companies that want to be where the action is,” said Governor Charlie Baker. “We welcome Selvita to Cambridge, and look forward to partnering with them to create jobs, and further economic growth and development.”
Selvita is a leading global drug discovery company founded in 2007 in Krakow, Poland. The company employs 265 people, including 86 PhDs and is engaged in provision of integrated drug discovery services as well as research and development of breakthrough therapies in the area of oncology.
The new office in Cambridge, Massachusetts will be the headquarters of Selvita Inc. and responsible for supporting the ongoing and future projects for our business partners from the East Coast, while the office in San Bruno, California will function to support the projects for our partners from the West Coast.
US drug discovery market “absolutely strategic” for the future development of Selvita
“The US drug discovery market is already the largest for Selvita and absolutely strategic for the future development of the company,” said Pawel Przewiezlikowski, the CEO of Selvita. “Both Greater Boston Area and San Francisco Bay Area are key to the whole biotechnology industry. Our presence in US will not only bring us closer both to our current and potential US clients, but at the same time will facilitate the bidirectional transfer of know-how between our labs in Poland and the partner base in the US. As the leading global drug discovery company we have already achieved a number of important milestones in Europe and now taking the leap across the Atlantic is a natural way for us to realize Selvita’s growth potential. We continuously invest in top-class facilities and equipment, and employ highly skilled and experienced professionals. Establishing permanent presence in the US is an investment in the quality of service and sales, and becoming even more easy to do business with for our US-based customers.”